Business Context and Reporting Period
Company: Regeneron Pharmaceuticals, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2003
Business Overview: Regeneron is a biopharmaceutical company focused on discovering, developing, and commercializing therapeutic products for serious medical conditions. The company has not yet generated sales or profits from the commercialization of its product candidates. Its core strategy involves combining basic scientific research with manufacturing and clinical development capabilities.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2003 |
Six Months Ended June 30, 2003 |
Six Months Ended June 30, 2002 |
|---|---|---|---|
| Total Revenues | $10,532 | $20,668 | $10,510 |
| Net Loss | ($28,736) | ($58,846) | ($55,868) |
| Net Loss Per Share (Basic/Diluted) | ($0.58) | ($1.25) | ($1.27) |
| Operating Expenses | $37,464 | $75,979 | $65,654 |
| Cash and Cash Equivalents | $129,659 | $129,659 | $69,374 |
| Total Marketable Securities | $137,487 | $137,487 | $193,684 |
| Long-Term Debt (Notes Payable) | $200,000 | $200,000 | $200,000 |
| Accumulated Deficit | ($482,921) | ($482,921) | ($424,075) |
Note: All figures in thousands except per share data. Total Marketable Securities includes current and non-current portions.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue for the six months ended June 30, 2003, increased to $20.7 million from $10.5 million in the prior year period. This was primarily driven by a significant increase in contract research and development revenue ($19.2 million vs. $5.4 million), largely due to the recognition of $13.7 million related to the new collaboration with Novartis.
- Contract Manufacturing Decline: Contract manufacturing revenue decreased to $1.5 million from $5.1 million in the prior year period because product inventory was not shipped to Merck & Co., Inc. during the first half of 2003. Shipments resumed in July 2003.
- Expense Increases: Total operating expenses rose to $76.0 million from $65.7 million. Research and development expenses increased to $68.1 million (from $56.2 million) due to increased clinical activity for AXOKINE and the IL-1 Trap.
- Liquidity Position: Cash and cash equivalents increased significantly to $129.7 million from $80.1 million at year-end 2002, bolstered by the Novartis collaboration payments and stock issuance.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Novartis Collaboration: In March 2003, Regeneron entered a collaboration with Novartis to jointly develop and commercialize the IL-1 Trap. Novartis made a $27.0 million non-refundable up-front payment and purchased $48.0 million of Regeneron common stock. Regeneron expects to receive up to $275.0 million in milestone payments upon regulatory approvals and revenue targets.
- Capital Resources: Management believes existing capital resources will enable the company to meet operating needs through at least the end of 2004. For the remainder of 2003, the company expects to incur approximately $10 million in capital expenditures.
- Product Pipeline:
- AXOKINE (Obesity): Phase III trial results showed statistically significant weight loss (6.2 lbs vs. 2.6 lbs placebo), though average loss was small and limited by antibody development in ~2/3 of subjects. Fast track designation received from FDA.
- IL-1 Trap (Rheumatoid Arthritis): Phase II trial fully enrolled; results expected in the second half of 2003.
- VEGF Trap (Cancer/Eye Diseases): Phase I trial ongoing; expected completion in first half of 2004.
Risks and Contingencies
- Legal Proceedings: Securities class action lawsuits were commenced in May 2003 alleging misstatements regarding the safety and efficacy of AXOKINE. The company believes the suits are without merit, but no provision for liability has been made.
- Development Risks: Significant risk exists regarding the failure of clinical trials, development of neutralizing antibodies (observed in AXOKINE trials), and delays in regulatory approval.
- Financing: The company has no established banking arrangements for short-term financing. Future funding may require additional public/private offerings or collaborations, which may not be available on acceptable terms.
- Accounting Standards: Adoption of SFAS No. 150 is not expected to have a material impact on financial statements.
Investor Verification Checklist
- Novartis Agreement Terms: Verify the specific milestones required for the $275 million in potential payments and the conditions under which the Novartis loans are forgiven.
- AXOKINE Antibody Data: Review the detailed data regarding the incidence of antibody development in the Phase III trial and its impact on long-term efficacy and potential market size.
- Merck Manufacturing Status: Confirm the timeline for the resumption of shipments to Merck & Co., Inc. and the impact on future contract manufacturing revenue.
- Cash Burn Rate: Assess the sustainability of the current cash position ($283.4 million in liquid assets) against the projected $10 million capital expenditure and ongoing R&D burn rate through 2004.
- Legal Exposure: Monitor the status of the securities class action lawsuits filed in May 2003 regarding AXOKINE disclosures.